Physician profile
Brian A Lea
NPI 1962665364
$3,809.54
in general payments reported to CMS, 2019-2025
27 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $12.18 · 2021: $177 · 2022: $477 · 2023: $1,276 · 2024: $950 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $794.67 | 2019-2025 | |
| Abbott Laboratories | $557.56 | 2019-2025 | Mitraclip, Cardiomems |
| Medtronic, INC. | $336.85 | 2021-2023 | Azure Xt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $303.44 | 2022-2025 | Verquvo |
| Inari Medical, INC. | $199.56 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $198.90 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $192.50 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $188.64 | 2022-2024 | Farxiga, Brilinta |
| Boston Scientific Corporation | $149.25 | 2019-2024 | Watchman Flx, Watchman Access System |
| Pfizer INC. | $147.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.05 | 2021-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $98.37 | 2023-2024 | Inpefa |
| Irhythm Technologies, INC. | $91.56 | 2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $76.05 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.83 | 2022-2024 | Lifevest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $50.65 | 2024 | Onpattro |
| Janssen Pharmaceuticals, INC | $38.53 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $36.87 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $29.56 | 2025 | |
| Elutia, INC. | $25.49 | 2019 | |
| Philips North America LLC | $22.63 | 2024 | (9124) Lm Undivided |
| Lantheus Medical Imaging, INC. | $20.12 | 2023 | Definity |
| Chiesi USA, INC. | $17.64 | 2024 | Cleviprex, Kengreal |
| Kiniksa Pharmaceuticals, LTD. | $17.57 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $14.87 | 2024 | Nexletol |
| Penumbra, INC. | $14.74 | 2022 | |
| Inspire Medical Systems, INC. | $13.59 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.